Rapidly evolving genome and epigenome editing technologies.
Molecular therapy : the journal of the American Society of Gene Therapy, 32(9): 2803-2806 PMID 39163859 DOI 10.1016/j.ymthe.2024.08.011
Abstract
Genome editing technologies are rapidly evolving, from the early zinc-finger nucleases, transcription activator-like effector nucleases (TALENs), and CRISPR-Cas9 (Figure 1, initial genome editing technologies), which generate double-strand breaks (DSBs), to base editing, which makes precise nucleobase conversion without inducing DSBs, and prime editing, which can carry out all types of edits without DSBs or donor DNA templates. The emergence of these revolutionary technologies offers us unprecedented opportunities for biomedical research and therapy development.